Therapeutic Protein Development Platforms
Therapeutic proteins can treat particular diseases by replacing abnormal or deficient proteins. Our company's therapeutic protein development platforms provide customers with a cost-effective and convenient solution. Our talented and highly trained team can provide you with high-quality therapeutic protein development services to ensure that we can quickly respond to the changing needs of your rare disease research projects.
Introduction to Therapeutic Proteins
Therapeutic proteins from natural sources, often at low levels, have become more widely available with the advent of genetic engineering. Scientists introduce genes containing instructions for specific proteins into animals, animal cells, or microbial cells and wait for the new organism to produce the required protein. The therapeutic protein works when delivered into the body, and the body responds to the protein as if it were naturally occurring. Therapeutic proteins can be classified according to molecular type:
- antibody-based drugs
- Fc fusion proteins
- blood factors
- bone morphogenetic proteins
- engineered protein scaffolds
- growth factors
Fig.1 Functional classification of therapeutic proteins. (Bahera, B.K., et al., 2021)
Therapeutic Protein for Rare Diseases
Therapeutic proteins are well tolerated, less likely to cause immune reactions, usually do not interfere with normal biological processes, and have fewer adverse reactions, so they are widely used in the treatment of rare diseases. There are already some cases of therapeutic proteins being used to treat rare diseases.
|Format in brief
|IL1R – Fc
|Cryopyrin-Associated Periodic Syndrome
|FVIII – Fc
|Peptide – Fc
|Type 2 Diabetes
|ActRIIb – Fc
The primary goal of our researchers is to help our customers develop effective alternative therapies for the treatment of proteins that are defective or dysfunctional due to mutations in individual genes associated with orphan diseases. Our protein replacement therapy development services target a variety of rare diseases, such as factor VII deficiency, hemophilia A, hemophilia B, fabry disease, antithrombin deficiency, mucopolysaccharidosis I, ADA deficiency, and hypophosphatasia.
Fusion proteins, also known as fusion tag proteins or chimeric proteins, are proteins produced by connecting two or more genes that originally encoded different proteins. With mature gene fusion technology and a chemical preparation platform, our company provides fusion tags preparation and fusion protein characterization services to support your preclinical research on rare diseases.
Recombinant protein production is a protein obtained by applying recombinant DNA or recombinant RNA technology. Our company's recombinant protein development platform has been greatly improved and built. From gene synthesis, and vector construction to protein expression, purification, and modification, we provide a one-stop recombinant protein development service.
Why Choose Us?
- Stringent quality control and testing
- Economical pricing and fast turnaround time
- Unmatched project management capability
- Tailored R&D solutions
- Professional technical support
- High data quality and reliable analysis
With a research team with extensive expertise, our company is confident to provide clients with therapeutic protein development services for rare diseases. We have the capabilities and resources to provide professional communication and problem-solving support to ensure that we can quickly respond to the changing needs of your rare disease therapy research projects. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
- Bahera, B.K., et al. "Therapeutic proteins: Production and delivery." Life Sciences Industry: From Laboratories to Commercialization of Research. Singapore: Springer Singapore, 2021. 127-207.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.